Synonym
MIRFENTANYL; Mirfentanil;
IUPAC/Chemical Name
N-(1-phenethylpiperidin-4-yl)-N-(pyrazin-2-yl)furan-2-carboxamide
InChi Key
BJZZDOLVVLWFHN-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H24N4O2/c27-22(20-7-4-16-28-20)26(21-17-23-11-12-24-21)19-9-14-25(15-10-19)13-8-18-5-2-1-3-6-18/h1-7,11-12,16-17,19H,8-10,13-15H2
SMILES Code
O=C(N(C1CCN(CCC2=CC=CC=C2)CC1)C3=NC=CN=C3)C4=CC=CO4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
376.46
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Robertson TBR, Gilbert N, Sutcliffe OB, Mewis RE. Hyperpolarisation of
Mirfentanil by SABRE in the Presence of Heroin. Chemphyschem. 2021 Jun
4;22(11):1059-1064. doi: 10.1002/cphc.202100165. Epub 2021 May 11. PMID:
33871116.
2: France CP, Winger G, Medzihradsky F, Seggel MR, Rice KC, Woods JH.
Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid
and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10. PMID:
1650830.
3: Carr DJ, Brockunier LL, Scott M, Bagley JR, France CP. Mirfentanil
antagonizes morphine-induced suppression of splenic NK activity in mice.
Immunopharmacology. 1996 Aug;34(1):9-16. doi: 10.1016/0162-3109(95)00051-8.
PMID: 8880221.
4: Lemmens HJ, Egan TD, Fiset P, Stanski DR. Pharmacokinetic/dynamic assessment
in drug development: application to the investigational opioid mirfentanil.
Anesth Analg. 1995 Jun;80(6):1206-11. doi: 10.1097/00000539-199506000-00024.
PMID: 7762853.
5: Lelas S, Gerak LR, Landers LK, Brandt MR, Bagley JR, Brockunier LL, France
CP. Pharmacological profile of a deuterium-substituted mirfentanil derivative,
OHM10579, in rhesus monkeys. Pharmacol Biochem Behav. 1998 Jul;60(3):665-75.
doi: 10.1016/s0091-3057(98)00046-x. PMID: 9678650.
6: Egan JA, Nugent RP, Filer CN. Mirfentanil and A-4334: Tritiation at high
specific activity. Appl Radiat Isot. 2010 Jan;68(1):120-1. doi:
10.1016/j.apradiso.2009.10.002. Epub 2009 Oct 13. PMID: 19875301.
7: Gauthier CA, Bagley JR, Brockunier LL, France CP. Daily mirfentanil induces
(cross-) tolerance to the rate-decreasing effects of morphine and not
mirfentanil. Behav Pharmacol. 1999 Sep;10(5):543-7. doi:
10.1097/00008877-199909000-00012. PMID: 10780260.
8: Buggé CJ, Tucker MD, Garcia DB, Kvalo LT, Wilhelm JA. Determination of
mirfentanil hydrochloride (A-3508.HCl) in human plasma by liquid chromatography-
mass spectrometry. J Pharm Biomed Anal. 1993 Sep;11(9):809-15. doi:
10.1016/0731-7085(93)80073-a. PMID: 8218525.
